New resource available view now
Recent Post
Related Posts
Healing from within: Gut Health Strategies That May Slow Alzheimer’s progression
Scientific breakthroughs have the potential to transform our understanding of disease and open new avenues for treatment. In Alzheimer’s research, one of the most recent and unexpected advances has
POTOMAC, MARYLAND – February 26, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
POTOMAC, MARYLAND – February 24, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Ascendiant Capital Markets has issued an updated equity research report
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
– Practice integrated neurology network expands enrollment capacity –
POTOMAC, MARYLAND – February 17, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company’s Phase 2 clinical stage program for agitation associated with Alzheimer’s disease. With this allowance, patent No. 3,095,729, titled “Method and Composition
